MEDP

MEDP

USD

Medpace Holdings Inc. Common Stock

$594.530+8.583 (1.465%)

Reaalajas hind

Healthcare
Diagnostics & Research
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$585.947

Kõrge

$599.990

Madal

$580.451

Maht

0.05M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

16.7B

Tööstusharu

Diagnostics & Research

Riik

United States

Kauplemisstatistika

Keskmine maht

0.34M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $250.05Praegune $594.530Kõrge $625

Seotud uudised

Reuters

Indian pharmacy retailer MedPlus profit jumps with store opening push

Medplus Health Services , one of India's top retail pharmacy chains, reported a 43.3% rise in second-quarter profit on Friday, driven by higher sales from new store openings and steady demand for its private label products.

Vaata rohkem
Indian pharmacy retailer MedPlus profit jumps with store opening push
Analyst Upgrades

TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462

TD Cowen analyst Charles Rhyee maintains Medpace Hldgs with a Sell and raises the price target from $356 to $462.

Vaata rohkem
TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462
Analyst Upgrades

Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485

Barclays analyst Luke Sergott maintains Medpace Hldgs with a Underweight and raises the price target from $425 to $485.

Vaata rohkem
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485
Analyst Upgrades

Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655

Mizuho analyst Ann Hynes maintains Medpace Hldgs with a Outperform and raises the price target from $575 to $655.

Vaata rohkem
Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655
Analyst Upgrades

Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins

Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.

Vaata rohkem
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
BusinessWire

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Revenue of $659.9 million in the third quarter of 2025 increased 23.7% from revenue of $533.3 million for the comparable prior-year period, representing a backlog conversion rate of 23.0%. Net new business awards

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.